Lannett Co. has received Food and Drug Administration approval for its 505(b)(2) New Drug Application (NDA) for morphine sulfate oral solution.


Lannett, morphine sulfate oral solution, New Drug Application, NDA, Arthur Bedrosian, 505(b)(2) New Drug Application, narcotic medication, pain relief medication














































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Lannett gets OK for morphine sulfate solution

June 24th, 2011

PHILADELPHIA – Lannett Co. has received Food and Drug Administration approval for its 505(b)(2) New Drug Application (NDA) for morphine sulfate oral solution.

Lannett said Friday that it expects to begin shipping the pain relief drug soon.

"This is first drug approval Lannett has received using a 505(b)(2) application," Arthur Bedrosian, president and chief executive officer of Lannett, said in a statement. "We applaud the dedicated efforts or our team and thank our shareholders for their patience and faith in our ability to relaunch this important medication."

A narcotic medication for moderate to severe pain, morphine sulfate oral solution totaled sales of about $31.7 million for the last 12 months at average wholesale prices, according to Wolters Kluwer data reported by Lannett.

Advertisement